Depression

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Meta-analysis reveals benefit of anti-inflammatory treatment for depression and anhedonia in individuals with inflammatory phenotype.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

Explore how lifestyle psychiatry transforms depression treatment through nutrition, exercise, sleep, and social connections for holistic recovery and resilience.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Explore updates from November 2025, including AI, drug updates, and more.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.